Quadruple primary malignancies of liver, bladder, lung and stomach in one patient

Ho-Young Yhim1, Hee Sun Kim4, Na-Ri Lee1,3, Jae-Yong Kwak1,3, Chang-Yeol Yim1,3, Ho Sung Park2, and Eun-Kee Song1,3

1Division of Hematology/Oncology, Department of Internal Medicine, and 2Department of Pathology, 3Advanced Research Cancer Center, Chonbuk National University Medical School, Jeonju, South Korea; 4Department of Nursing, Jeonbuk Science College, Jeongeup, Korea

ABSTRACT

Multiple primary malignancies are defined as two or more malignancies in an individual without any relationship between the tumors. Because of advances in the early detection, treatment, and supportive care for cancer, the number of cancer survivors has been gradually increasing, and this has led to an increase in the possible occurrence of subsequent malignancies. Recently, there have been reports that smoking is associated with a specific genetic mutation (the tumor suppressor gene TP53), and this genetic predisposition may be related to the development of multiple primary malignancies. Here we present a rare case of quadruple primary malignancies of the liver, bladder, lung and stomach, some of which possibly linked to smoking-related TP53 mutation. Because of its extreme rarity and the clear relationship between multiple primary malignancies and smoking-related TP53 mutation, we report this case along with a review of the relevant literature. Free full text available at www.tumorionline.it

Tumori, 96: 787-791, 2010

Key words: multiple primary neoplasms, tumor suppressor gene TP53, liver neoplasm, bladder neoplasm, lung neoplasm, stomach neoplasm.

Acknowledgments: This study was supported by a grant from the National R&D Program for Cancer Control, Ministry of Health & Welfare, Republic of Korea (0620220-1).

Correspondence to: Eun-Kee Song, Department of Internal Medicine, Chonbuk National University Medical School, San 2-20 Geumam-dong, Jeonju, 561-712, South Korea. Tel +82-63-250-1245; fax 82-63-254-1609; e-mail eksong@chonbuk.ac.kr

Received August 25, 2009; accepted December 1, 2009.